Abstract: A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 24-45% CaO, 34-50% SiO2, 0-25% Na2O, 5-17% P2O5, 0-5% MgO and 0-1% CaF2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.

Abstract: An optical module may include a case, an optical assembly, a circuit board interface positioned on the case, and a circuit board attached to the case through the circuit board interface. The optical assembly may be arranged in the case. The circuit board may include a first area that may electrically connect the circuit board to the optical assembly. The circuit board may also include a second area that may secure the circuit board to the circuit board interface. An optical module manufacturing method is also provided.

Abstract: A locking arrangement secures together first and second panels. The arrangement includes locking tabs (54, 56, 58) projecting from an end edge (64) of the first panel (12) and locking slits (50a, 50b, 50c) in the second panel (28). Each locking slit is provided for receiving a respective one of the locking tabs. The locking tabs and the locking slits are engageable by relative sliding movement with each other. At least one of the locking tabs and locking slits is configured to secure the first and second panels in a first overlapping position while at least another one of the locking tabs and locking slits is configured to secure the first and second panels in a second overlapping position.

Abstract: An apparatus for throttling uplink data based on a temperature state is provided. The apparatus includes a temperature sensor, a processor and a memory. The temperature sensor senses an internal temperature of the apparatus. The memory is operatively coupled to the processor. The processor is configured to execute a program code stored in the memory to: compare the internal temperature to a corresponding temperature range according to a predetermined table of temperature ranges; and control a packet buffer to adjust a current data rate to a corresponding target data rate according to the comparison result.

Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is directed to compounds and pharmaceutical formulations comprising these compounds which are useful as O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors, and thus may be useful for the treatment of certain disorders such as Alzheimer's disease including reducing NFTs and/or hyperphosphorylated tau. The invention is also directed to use of the compounds as O-GlcNAcase imaging agents.

Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.

Abstract: Disclosed is a system for performing online data queries and purchasing advertisements associated with business listings. The system for performing online data queries is a distributed computer system with a plurality of server nodes each fully redundant and capable of processing a user query request. Each server node includes a data query cache and other caches that may be used in performing data queries. The data query, as well as request allocation, is performed in accordance with an adaptive partitioning technique with a bias towards an initial partitioning scheme. Generic objects are created and used to represent business listings upon which the user may perform queries. Various data processing and integration techniques are included which enhance data queries. An update technique is used for synchronizing data updates as needed in updating the plurality of server nodes.

Abstract: The present invention relates to a pH buffered bioactive glass, and its preparation process and use. The pH buffered bioactive glass comprises SiO2, CaO, Na2O, and P2O5, and further comprises solid acidic particles or a Tris buffer solution. The pH buffered bioactive glass can regulate the pH of formulations comprising bioactive glass, and has a good therapeutic effect with a low dosage.

Abstract: A USB device enumeration process implemented in a USB device is described. The USB device first detects a type of the operating system (OS) of the USB host connected to the device, and performs device enumeration using a process selected from multiple stored processes based on the detected host OS type. To detect the host OS type, the USB device first presents itself to the host as a USB MSD or HID, performs device enumeration to collect OS behavior factors from the host, and determines the OS type from the OS behavior factors. Thereafter, the USB device performs actual device enumeration by presenting itself as the USB device it actually is, using an enumeration process specific to the detected host OS type. The multiple stored enumeration processes are customer configurable. Further, a method is provided to stop an enumeration process when the host is in a BIOS stage.

Abstract: The invention is directed to compounds for selectively inhibiting glycosidases, uses of the compounds and pharmaceutical compositions including the compounds, and methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, and/or accumulation or deficiency of O-GlcNAc.

Abstract: Transmitting an indication of a default configuration for a sub-frame having a downlink transmission portion and an uplink transmission portion; transmitting an indication of a preferred configuration for said sub-frame; and scheduling transmissions to and/or from a communication device according to said preferred sub-frame configuration.

Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A USB device enumeration process implemented in a USB device is described. The USB device first detects a type of the operating system (OS) of the USB host connected to the device, and performs device enumeration using a process selected from multiple stored processes based on the detected host OS type. To detect the host OS type, the USB device first presents itself to the host as a USB MSD or HID, performs device enumeration to collect OS behavior factors from the host, and determines the OS type from the OS behavior factors. Thereafter, the USB device performs actual device enumeration by presenting itself as the USB device it actually is, using an enumeration process specific to the detected host OS type. The multiple stored enumeration processes are customer configurable. Further, a method is provided to stop an enumeration process when the host is in a BIOS stage.

Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Abstract: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Abstract: A compound having the structure useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, angina pectoris, thromboses, restenoses, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver in a human or animal patient.

Abstract: A method of preparing electrospun fiber tubular material comprises: using single metal rod template or two-dimensional or three-dimensional metal rod combined-template which has cross structure and is composed of the said single metal rod templates to prepare tubular electrospun fiber material by controlling electrospinning process parameters. The method could control the macro-structure and micro-structure of the tubular electrospun fiber material by adjusting template parameters. The tubular electrospun fiber material obtained from the method could be used in such fields as biomedical material, tissue engineering scaffold, photo-electric material, filtering material and sensor etc.

Abstract: The present invention provides methods for distributed resource management for enhanced dedicated channel. One method of communication with at least one base station includes determining at least one short-term entity associated with the at least one base station and providing the at least one short-term entity to a radio network controller. Another method includes receiving at least one short-term entity associated with the at least one base station and allocating at least one long-term resource based upon the at least one short-term entity.

Abstract: A method of manufacturing a resorbable, macroporous bioactive glass scaffold comprising approximately 24-45% CaO, 34-50% SiO2, 0-25% Na2O, 5-17% P2O5, 0-5% MgO and 0-1% CaF2 by mass percent, produced by mixing with pore forming agents and specified heat treatments.